Silver Gene Medicine-B (02591) said its board has been notified that founder, Chairman, Executive Director and General Manager Wang Qinghua, along with Executive Directors Jiang Fan, Xu Wenjie and Huang Bing, have each voluntarily undertaken not to sell any shares or interests they directly or indirectly hold in the company for six months starting from Aug. 15, 2026, according to ETNet.
The company said the pledge reflects their confidence in its future prospects and long-term development. Aug. 15, 2026 is the date when the lock-up period for the controlling shareholder under the company’s global offering on the Main Board of the Hong Kong Stock Exchange expires.